Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

Spain: Researchers have found in a real-world cohort of patients with giant cell arteritis–associated aortitis, published in ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

New Afrezza prescribing information outlines higher starting dose conversions for patients transitioning from mealtime insulin to improve glycemic control.

Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...

Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...